scholarly journals Corrigendum to “Protective Effect of Ginkgo biloba and Magnetized Water on Nephropathy in Induced Type 2 Diabetes in Rat”

2018 ◽  
Vol 2018 ◽  
pp. 1-1
Author(s):  
Ahmed E. Zayed ◽  
Ahmed Saleh ◽  
Asmaa M. S. Gomaa ◽  
Mahmoud Abd-Elkareem ◽  
Mamdouh M. Anwar ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Protective Effect ◽  
Ginkgo Biloba ◽  
Magnetized Water

scholarly journals Protective Effect of Ginkgo biloba and Magnetized Water on Nephropathy in Induced Type 2 Diabetes in Rat

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Ahmed E. Zayed ◽  
Ahmed Saleh ◽  
Asmaa M. S. Gomaa ◽  
Mahmoud Abd-Elkareem ◽  
Mamdouh M. Anwar ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Protective Effect ◽  
Ginkgo Biloba ◽  
Kidney Tissue ◽  
Diabetic Rat ◽  
Control Group ◽  
Blood Levels ◽  
Tissue Samples ◽  
Magnetized Water

We aimed in our current study to explore the protective effect of Ginkgo biloba (GB) and magnetized water (MW) against nephrotoxicity associating induced type 2 diabetes mellitus in rat. Here, we induced diabetes by feeding our lab rats on a high fat-containing diet (4 weeks) and after that injecting them with streptozotocin (STZ). We randomly divided forty rats into four different groups: nontreated control (Ctrl), nontreated diabetic (Diabetic), Diabetic+GB (4-week treatment), and Diabetic+MW (4-week treatment). After the experiment was finished, serum and kidney tissue samples were gathered. Blood levels of glucose, triglycerides, cholesterol, creatinine, and urea were markedly elevated in the diabetic group than in the control group. In all animals treated with GB and MW, the levels of urea, creatinine, and glucose were significantly reduced (all P<0.01). GB and MW attenuated glomerular and tubular injury as well as the histological score. Furthermore, they normalized the contents of glutathione reductase and SOD2. In summary, our data showed that GB and MW treatment protected type 2 diabetic rat kidneys from nephrotoxic damages by reducing the hyperlipidemia, uremia, oxidative stress, and renal dysfunction.

scholarly journals α-CGRP disrupts amylin fibrillization and regulates insulin secretion: implications on diabetes and migraine

2021 ◽  
Vol 12 (16) ◽  
pp. 5853-5864
Author(s):  
Amber L. H. Gray ◽  
Aleksandra Antevska ◽  
Benjamin A. Link ◽  
Bryan Bogin ◽  
Susan J. Burke ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Secretion ◽  
Protective Effect ◽  
Human Insulin ◽  
Human Amylin

CGRP concentration is elevated in migraine conditions. The protective effect of migraine against type 2 diabetes is attributed to the ability of CGRP to remodel human amylin aggregation and to suppress the secretion of mouse insulin 2 (the orthologue of human insulin).

scholarly journals TGF-β1 Gene Polymorphism in Codon 10 +869*C/T and Codon 25 +915*G/C Positions in Iraqi Patients with Type 2 Diabetes Mellitus

2016 ◽  
Vol 10 (2) ◽  
pp. 47-51
Author(s):  
Ihsan A. Hussein
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Protective Effect ◽  
Control Sample ◽  
Amplification Refractory Mutation System ◽  
Blood Samples ◽  
Increased Risk ◽  
Tgf Β1

This study included 50 blood samples that were collected from patients with age ranged between 35-65 years. Thirty samples were collected from patients with Type 2 Diabetes Mellitus (T2DM), while 20 blood samples were collected from healthy individuals as a control sample. The polymorphism results of TGF-β1 gene in codon 10: +869*C/T position by using amplification refractory mutation system (ARMS-PCR) showed that the T allele was suggested to have a protective effect, while C allele was associated with an increased risk of T2DM. The TT and CT were suggested to have a protective effect, while CC genotype was associated with an increased risk of T2DM. The polymorphism results of TGF-β1 gene in codon 25: +915*G/C position in samples showed that the G allele was suggested to have a protective effect, while C allele was associated with an increased risk of T2DM. The GC genotype was suggested to have a protective effect, while GG and CC genotypes were associated with an increased risk of T2DM.

scholarly journals Whole-grain consumption and transcription factor-7-like 2 (TCF7L2) rs7903146: gene–diet interaction in modulating type 2 diabetes risk

2008 ◽  
Vol 101 (4) ◽  
pp. 478-481 ◽  
Author(s):  
Eva Fisher ◽  
Heiner Boeing ◽  
Andreas Fritsche ◽  
Frank Doering ◽  
Hans-Georg Joost ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Transcription Factor ◽  
Protective Effect ◽  
Specific Effect ◽  
Whole Grains ◽  
Hazard Ratio ◽  
Diabetes Risk ◽  
Inverse Association ◽  
Whole Grain

Whole grains are known to influence postprandial glucose response and insulin demand and are inversely associated with diabetes risk. Genetic variation of the transcription factor-7-like 2 encoding gene (TCF7L2) is assumed to promote an early insulin secretory defect and has been consistently attributed to the risk of developing type 2 diabetes. The present study examined the hypothesis that the protective effect of whole grains might be attenuated in the presence of the rs7903146 risk-conferring T-allele. We employed a case–cohort study of 2318 randomised individuals and 724 incident type 2 diabetes cases from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort. Multivariate Cox regression was used to estimate relative risks of diabetes including product terms testing for the genotype-specific effect modification of dietary whole grain. Dietary intake of whole grains was assessed by a validated FFQ. The TCF7L2 rs7903146 T-allele was associated with type 2 diabetes (hazard ratio = 1·51; 95 % CI 1·21, 1·87) and modified the inverse association between whole-grain intake and diabetes risk (P = 0·016 for interaction). While whole-grain intake was inversely associated with diabetes risk among rs7903146 CC homozygote carriers (hazard ratio for 50 g portion per d = 0·86; 95 % CI 0·75, 0·99), the T-allele negated the protective effect of whole-grain intake (hazard ratio among T-allele carriers for 50 g portion per d = 1·08; 95 % CI 0·96, 1·23). These data provide evidence that the beneficial effect of whole-grain intake on diabetes risk is modified by TCF7L2 rs7903146.

scholarly journals Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial

2021 ◽  
Author(s):  
Taha Sen ◽  
Jingwei Li ◽  
Brendon L. Neuen ◽  
Clare Arnott ◽  
Bruce Neal ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Protective Effect ◽  
Cox Regression ◽  
Cardiovascular Death ◽  
High Cardiovascular Risk ◽  
Cardiovascular Assessment ◽  
Glomerular Filtration Rate Decline ◽  
End Stage

Background Studies have suggested that sodium glucose co‐transporter 2 inhibitors exert anti‐inflammatory effects. We examined the association of baseline growth differentiation factor‐15 (GDF‐15), a marker of inflammation and cellular injury, with cardiovascular events, hospitalization for heart failure (HF), and kidney outcomes in patients with type 2 diabetes in the CANVAS (Canagliflozin Cardiovascular Assessment Study) and determined the effect of the sodium glucose co‐transporter 2 inhibitor canagliflozin on circulating GDF‐15. Methods and Results The CANVAS trial randomized 4330 people with type 2 diabetes at high cardiovascular risk to canagliflozin or placebo. The association between baseline GDF‐15 and cardiovascular (non‐fatal myocardial infarction, non‐fatal stroke, cardiovascular death), HF, and kidney (40% estimated glomerular filtration rate decline, end‐stage kidney disease, renal death) outcomes was assessed using multivariable adjusted Cox regression models. During median follow‐up of 6.1 years (N=3549 participants with available samples), 555 cardiovascular, 129 HF, and 137 kidney outcomes occurred. Each doubling in baseline GDF‐15 was significantly associated with a higher risk of cardiovascular (hazard ratio [HR], 1.2; 95% CI, 1.0‒1.3), HF (HR, 1.5; 95% CI, 1.2‒2.0) and kidney (HR, 1.5; 95% CI, 1.2‒2.0) outcomes. Baseline GDF‐15 did not modify canagliflozin’s effect on cardiovascular, HF, and kidney outcomes. Canaglifozin treatment modestly lowered GDF‐15 compared with placebo; however, GDF‐15 did not mediate the protective effect of canagliflozin on cardiovascular, HF, or kidney outcomes. Conclusions In patients with type 2 diabetes at high cardiovascular risk, higher GDF‐15 levels were associated with a higher risk of cardiovascular, HF, and kidney outcomes. Canagliflozin modestly lowered GDF‐15, but GDF‐15 reduction did not mediate the protective effect of canagliflozin.

scholarly journals ENDOTHELIAL PROTECTIVE EFFECT OF LIRAGLUTIDE IN TYPE 2 DIABETES MELLITUS

2018 ◽  
Vol 24 (1) ◽  
pp. 81-92 ◽  
Author(s):  
A. V. Simanenkova ◽  
M. N. Makarova ◽  
M. I. Butomo ◽  
T. D. Vlasov ◽  
E. V. Shlyakhto
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Protective Effect
Sign in / Sign up

Export Citation Format

Share Document